You are here

Phase 2 Study Showed Significant Relief of Acute Pain


Treatment with the NaV1.8 Inhibitor VX-150 Showed Significant Relief of Acute Pain in a Phase 2 Proof-of-Concept Study 


February 14, 2018

Vertex announced positive results from a Phase 2 study of VX-150, an inhibitor of sodium channel 1.8 (NaV1.8), in acute pain following bunionectomy surgery. In the study, treatment with VX-150 showed statistically significant relief of acute pain compared to placebo. This is the second positive proof-of-concept study for VX-150, providing further validation for NaV1.8 inhibition in the treatment of pain. Vertex also recently initiated a Phase 1 study of a second NaV1.8 inhibitor, VX-128, in healthy volunteers.